PharVision Advisers’s REV Group REVG Stock Holding History

PharVision Advisers’s Portfolio REVG Stock Details REVG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-6,437	Closed	-$365K	–	954
2025 Q3	$365K	Buy	+6,437	New	+$342K	0.21%	116

Other funds holding REVG

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

HGIM

High Ground Investment Management London, United Kingdom $1.14B AUM 29.32% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PharVision Advisers's REVG Position: Q4 2025 in Review

PharVision Advisers sold out of REV Group (REVG) in Q4 2025, closing a stake of 6,437 shares — an estimated $365K sold.

PharVision Advisers first reported a position in REVG in Q3 2025 and held it in 1 quarter. The position peaked at $365K in Q3 2025. 323 funds tracked by Wall St. Rank hold REVG as of Q4 2025.

PharVision Advisers reported no remaining REV Group position as of Q4 2025 after selling out during the quarter.
PharVision Advisers sold 6,437 REV Group shares in Q4 2025, an estimated $365K.
PharVision Advisers first reported a position in REV Group in Q3 2025 and held it in 1 quarter.
PharVision Advisers's REV Group position peaked at $365K in Q3 2025.
323 funds tracked by Wall St. Rank held REV Group as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.